Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein (Q40262839)

19 September 2017

Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein (English)

1 reference

19 September 2017

Yang G

1

1 reference

19 September 2017

Thompson MA

series ordinal

2

1 reference

19 September 2017

Brandt SJ

series ordinal

3

1 reference

19 September 2017

Hiebert SW

series ordinal

4

1 reference

19 September 2017

language of work or name

English

0 references

publication date

26 June 2006

1 reference

19 September 2017

1 reference

19 September 2017

26

1 reference

19 September 2017

1

1 reference

19 September 2017

91-101

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1209760

19 September 2017

0 references

cites work

ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Modulating molecular chaperone Hsp90 functions through reversible acetylation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Acetylation inactivates the transcriptional repressor BCL6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Four Birds with One Stone: RAPA as Potential Anticancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Clinical development of histone deacetylase inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Reversible tumorigenesis by MYC in hematopoietic lineages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Linking the epigenetic 'language' of covalent histone modifications to cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Multiple regions of ETO cooperate in transcriptional repression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Translating the Histone Code

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Association of MTG8 (ETO/CDR), a leukemia-related protein, with serine/threonine protein kinases and heat shock protein HSP90 in human hematopoietic cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Ribonuclease H attack of leukaemic fused transcripts AML1-MTG8 (ETO) by DNA/RNA chimeric hammerhead ribozymes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Translating the histone code into leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Cutaneous T-cell lymphoma: a paradigm for biological therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Structure and functional relationships of Hsp90.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Cleavage of AML1/MTG8 by asymmetric hammerhead ribozymes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209760

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1209760

1 reference

Dimensions Publication ID

19 September 2017

0 references

1 reference